Suppliers and packagers for GLATOPA

GLATOPA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sandoz	GLATOPA	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	090218	ANDA	Sandoz Inc	0781-3234-34	30 BLISTER PACK in 1 CARTON (0781-3234-34) / 1 SYRINGE, GLASS in 1 BLISTER PACK / 1 mL in 1 SYRINGE, GLASS (0781-3234-71)	2015-06-18
Sandoz	GLATOPA	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	090218	ANDA	Bryant Ranch Prepack	63629-8815-1	30 BLISTER PACK in 1 CARTON (63629-8815-1) / 1 SYRINGE, GLASS in 1 BLISTER PACK / 1 mL in 1 SYRINGE, GLASS	2015-06-18
Sandoz	GLATOPA	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	206921	ANDA	Sandoz Inc	0781-3250-89	12 BLISTER PACK in 1 CARTON (0781-3250-89) / 1 SYRINGE, GLASS in 1 BLISTER PACK / 1 mL in 1 SYRINGE, GLASS (0781-3250-71)	2018-02-12

Glatopa Supplier Landscape Analysis

Last updated: February 19, 2026

This report analyzes the supply chain for Glatopa (glatiramer acetate injection), a biosimilar to Copaxone. Key manufacturers and their geographical distribution are identified, along with insights into production capacity and regulatory approvals that shape market competition.

Who are the Primary Manufacturers of Glatopa?

Glatopa is manufactured by a limited number of pharmaceutical companies, primarily due to the complexity of producing glatiramer acetate and the associated regulatory hurdles. These companies have invested significantly in developing and scaling up production processes that meet stringent quality and efficacy standards.

• Sandoz (a Novartis division): Sandoz is a leading global biosimilar manufacturer and a key player in the glatiramer acetate market. Their commitment to biosimilar development positions them as a significant supplier of Glatopa in various regions. Sandoz's involvement indicates a focus on established markets with robust regulatory frameworks.
• Teva Pharmaceutical Industries: As the originator of Copaxone, Teva also manufactures its own generic version, which is closely comparable to Glatopa. While not directly a "Glatopa" manufacturer in the biosimilar sense, Teva's established production capabilities and market presence in glatiramer acetate are critical context for understanding the competitive supply environment. Teva's dual role as originator and generic producer provides a unique competitive dynamic.
• Momenta Pharmaceuticals: Momenta was a significant developer and manufacturer of glatiramer acetate products. Their contributions included the development of complex injectable generics and biosimilars. The acquisition of Momenta by Johnson & Johnson in 2020 integrated their glatiramer acetate assets and manufacturing expertise into J&J's broader pharmaceutical portfolio. This acquisition consolidates a portion of the glatiramer acetate supply chain under a larger entity.

What are the Key Production Regions and Their Impact?

The production of Glatopa and its related glatiramer acetate products is concentrated in specific geographical regions, influencing supply chain logistics, cost structures, and regulatory oversight.

• United States: Production facilities in the U.S. are subject to rigorous FDA oversight, ensuring high standards for quality and safety. Companies operating in the U.S. often benefit from proximity to a large patient population and established distribution networks. Sandoz has manufacturing operations and R&D centers in the U.S. that contribute to their global supply capabilities.
• Europe: European countries, particularly those with strong pharmaceutical manufacturing infrastructure, are also key production hubs. These regions are regulated by the European Medicines Agency (EMA), which enforces similar quality and efficacy standards to the FDA. European manufacturing can offer advantages in terms of skilled labor and access to specialized raw materials.
• Israel: As the home of Teva, Israel plays a crucial role in the production of glatiramer acetate. Teva's extensive manufacturing network, with significant operations in Israel, has historically been a primary source for Copaxone and its generic versions. This established presence contributes to a stable, albeit concentrated, supply base.

The geographical distribution of manufacturing sites is a critical factor for supply chain resilience. A concentration of manufacturing in fewer regions can increase vulnerability to geopolitical events, natural disasters, or localized regulatory changes. Diversification of production sites across different continents is essential for mitigating these risks.

What is the Regulatory Status and Approval History of Glatopa?

The approval process for biosimilars like Glatopa is complex and varies by regulatory agency. Successful navigation of these pathways is a prerequisite for market entry and commercialization.

• U.S. Food and Drug Administration (FDA): Glatopa was approved by the FDA as a biosimilar. The FDA's approval process for biosimilars requires demonstrating high similarity to the reference product in terms of molecular characteristics, biological activity, and clinical outcomes.
  • Glatopa's initial approval as a biosimilar to Copaxone marked a significant step in making this important therapy more accessible in the U.S. market.
  • The FDA's pathway for biosimilars (21 CFR Part 314 Subpart I) is based on a comprehensive scientific evaluation.
• European Medicines Agency (EMA): Glatopa has also received approval from the EMA, indicating its acceptance within the European regulatory framework for biosimilars. The EMA follows a similar rigorous scientific review process, focusing on analytical, non-clinical, and clinical data to establish biosimilarity.
  • The EMA's guidelines for biosimilar approval are well-established and provide a clear pathway for manufacturers.
• Other Regulatory Bodies: Approvals in other major markets, such as Canada and Japan, are also pursued by manufacturers to expand global market access. The specific requirements and timelines for approval differ across these jurisdictions, necessitating tailored regulatory strategies.

The strength and clarity of regulatory pathways significantly influence investment decisions in biosimilar manufacturing. Countries with established and predictable biosimilar approval processes are more attractive for R&D and production.

What are the Key Raw Material and Intermediate Suppliers?

The production of glatiramer acetate is a multi-step chemical synthesis process that relies on a consistent supply of specific raw materials and intermediates. Identifying these suppliers is crucial for understanding potential bottlenecks and cost drivers.

• Amino Acids: Glatiramer acetate is a synthetic polypeptide composed of four amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine.
  • Key Suppliers: Major chemical companies specializing in amino acid production are the primary sources for these critical building blocks. Companies like Ajinomoto, Evonik Industries, and CJ CheilJedang are significant global suppliers of pharmaceutical-grade amino acids. Sourcing from multiple suppliers is essential for supply chain security.
• Other Chemical Reagents: The synthesis process involves various other chemical reagents, solvents, and catalysts.
  • Key Suppliers: Global chemical distributors and manufacturers such as Sigma-Aldrich (Merck KGaA), Thermo Fisher Scientific, and BASF provide a wide range of these necessary chemicals. The purity and consistency of these reagents are paramount.
• Peptide Synthesis Expertise: While not a raw material supplier in the traditional sense, companies with specialized expertise in solid-phase or solution-phase peptide synthesis can play a role in providing custom intermediates or specialized services. This can include contract manufacturing organizations (CMOs) with advanced peptide capabilities.

The supply chain for raw materials is often global. Fluctuations in the availability or price of these raw materials, driven by factors like agricultural yields (for some amino acid precursors), geopolitical stability, or shipping costs, can directly impact the production cost and availability of Glatopa. Ensuring multiple qualified suppliers for critical raw materials is a standard risk mitigation strategy in pharmaceutical manufacturing.

What is the Production Capacity and Scalability Outlook?

The production capacity for glatiramer acetate is a critical determinant of market supply and pricing dynamics. Scalability is essential to meet growing demand and respond to market competition.

• Existing Capacity: The major manufacturers, including Sandoz and facilities that were formerly Momenta's, possess substantial manufacturing capacity for injectable complex generics and biosimilars. This capacity is geared towards producing multi-million dollar revenue streams from these high-value therapies.
  • Sandoz: As a dedicated biosimilar and generic manufacturer, Sandoz has invested in flexible manufacturing platforms that can be scaled to meet market demand for products like Glatopa. Their global network of facilities allows for distributed manufacturing.
  • Johnson & Johnson (via Momenta acquisition): The integration of Momenta's assets into J&J's R&D and manufacturing infrastructure provides access to established production lines and expertise in complex injectables.
  • Teva: Teva's long-standing experience with Copaxone means they have significant dedicated capacity for glatiramer acetate production, contributing to overall market supply.
• Scalability Factors:
  • Technology Transfer: The ability to transfer manufacturing processes to new facilities or scale up existing ones is dependent on robust process validation and technology transfer protocols.
  • Regulatory Approvals for New Sites: Any expansion to new manufacturing sites requires separate regulatory approval, which can be time-consuming.
  • Raw Material Availability: Scalability is directly linked to the consistent availability of key raw materials and intermediates from qualified suppliers.
  • Investment in Automation and Advanced Manufacturing: Modern pharmaceutical manufacturing relies heavily on automation and advanced process control to ensure consistency and efficiency, which are crucial for scaling production.

The outlook for production capacity is generally robust, driven by the significant market value of glatiramer acetate therapies. However, ensuring long-term supply stability requires continuous investment in manufacturing infrastructure and proactive management of the raw material supply chain.

What are the Intellectual Property and Patent Landscape Considerations?

The patent landscape surrounding glatiramer acetate is complex, influencing the market entry of biosimilars and generics.

• Composition of Matter Patents: These patents, covering the glatiramer acetate molecule itself, are fundamental. For biosimilars, these patents are typically expired or nearing expiration by the time of market entry.
  • Copaxone originator patents have expired in major markets, paving the way for generic and biosimilar competition.
• Process Patents: Patents covering specific manufacturing processes, purification methods, or formulation techniques can still provide protection. Biosimilar developers must demonstrate that their manufacturing processes do not infringe on existing valid process patents.
  • Glatopa Development: Sandoz and Momenta invested in developing proprietary manufacturing processes that were distinct from the originator's, aiming to circumvent existing process patents and establish their own intellectual property.
• Formulation and Delivery Patents: Patents related to specific formulations (e.g., excipients, stability enhancers) or delivery devices (e.g., pre-filled syringes, autoinjectors) can extend market exclusivity.
  • Different dosing regimens (e.g., daily vs. thrice-weekly injections) have been subject to patent strategies. Glatopa's approval often encompasses specific dosage forms and strengths that align with therapeutic indications.
• Litigation: The pharmaceutical industry, particularly in the complex generics and biosimilar space, is characterized by extensive patent litigation. Challenges to patent validity or arguments of non-infringement are common.

Understanding the patent landscape is critical for any company considering investment in the production or distribution of glatiramer acetate. Freedom-to-operate analyses are essential to avoid costly litigation and ensure market access.

Key Takeaways

• Glatopa production is concentrated among a few key manufacturers, including Sandoz and former Momenta assets now under Johnson & Johnson, with Teva being a major player in the broader glatiramer acetate market.
• Manufacturing is primarily located in the United States, Europe, and Israel, subject to stringent FDA and EMA regulations.
• The supply chain for critical raw materials, particularly the four constituent amino acids and various chemical reagents, relies on global suppliers, necessitating robust sourcing strategies.
• Production capacity is substantial, with established players possessing the infrastructure to scale operations, but long-term stability depends on continuous investment and supply chain management.
• The intellectual property landscape, particularly the expiration of composition of matter patents for the originator product, has enabled biosimilar and generic market entry, though process and formulation patents remain relevant.

Frequently Asked Questions

What is the difference between a biosimilar and a generic drug?

A biosimilar is a biological product that is highly similar to an already approved biological product, known as the reference product, with no clinically meaningful differences in terms of safety, purity, and potency. A generic drug is a chemically synthesized drug that is an exact copy of an approved brand-name drug. Glatopa is a biosimilar because glatiramer acetate is a complex biological molecule.

How does regulatory approval differ for biosimilars compared to small molecule generics?

Biosimilar approval requires extensive analytical, non-clinical, and clinical data to demonstrate high similarity to the reference product. Generic drug approval typically requires demonstrating bioequivalence, meaning the rate and extent to which the active ingredient is absorbed into the bloodstream are not significantly different from the reference product.

What are the primary challenges in manufacturing glatiramer acetate?

Manufacturing glatiramer acetate is challenging due to its complex polypeptide structure, which requires precise control over polymerization and purification processes. Ensuring lot-to-lot consistency, maintaining high purity, and scaling up production while adhering to strict Good Manufacturing Practices (GMP) are significant hurdles.

How do fluctuating raw material costs impact the price of Glatopa?

The price of Glatopa is influenced by the cost of its key raw materials, including amino acids and chemical reagents. If the prices of these inputs increase due to supply shortages, geopolitical factors, or changes in agricultural yields, manufacturers may face higher production costs, which can be passed on to consumers through higher drug prices.

What is the role of contract manufacturing organizations (CMOs) in the glatiramer acetate supply chain?

CMOs with expertise in complex peptide synthesis and sterile injectable manufacturing can play a vital role in the Glatopa supply chain. They can offer specialized manufacturing capabilities, help scale production, and provide flexibility for pharmaceutical companies that may not have sufficient in-house capacity or specific technical expertise.

Citations

[1] Sandoz. (n.d.). Glatiramer Acetate. Retrieved from [Relevant Sandoz Product Page or Press Release - Placeholder, specific URL would be needed] [2] Teva Pharmaceutical Industries Ltd. (n.d.). Glatiramer Acetate Injection. Retrieved from [Relevant Teva Product Page or Press Release - Placeholder, specific URL would be needed] [3] Johnson & Johnson. (2020, March 2). Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals. [Press release]. Retrieved from [Placeholder for J&J Press Release URL] [4] U.S. Food and Drug Administration. (n.d.). Biosimilars. Retrieved from [Placeholder for FDA Biosimilars Page URL] [5] European Medicines Agency. (n.d.). Biosimilar medicines. Retrieved from [Placeholder for EMA Biosimilar Medicines Page URL] [6] Ajinomoto Co., Inc. (n.d.). Amino Acids. Retrieved from [Relevant Ajinomoto Product Page - Placeholder, specific URL would be needed] [7] Evonik Industries AG. (n.d.). Amino Acids. Retrieved from [Relevant Evonik Product Page - Placeholder, specific URL would be needed] [8] CJ CheilJedang. (n.d.). Amino Acids. Retrieved from [Relevant CJ CheilJedang Product Page - Placeholder, specific URL would be needed] [9] Merck KGaA. (n.d.). Sigma-Aldrich Products. Retrieved from [Placeholder for Sigma-Aldrich Product Search URL] [10] Thermo Fisher Scientific. (n.d.). Chemicals & Reagents. Retrieved from [Placeholder for Thermo Fisher Scientific Product Search URL] [11] BASF SE. (n.d.). Chemicals. Retrieved from [Relevant BASF Product Page - Placeholder, specific URL would be needed]